Literature DB >> 26277280

Challenges and achievements in the therapeutic modulation of aquaporin functionality.

Eric Beitz1, André Golldack2, Monja Rothert2, Julia von Bülow2.   

Abstract

Aquaporin (AQP) water and solute channels have basic physiological functions throughout the human body. AQP-facilitated water permeability across cell membranes is required for rapid reabsorption of water from pre-urine in the kidneys and for sustained near isosmolar water fluxes e.g. in the brain, eyes, inner ear, and lungs. Cellular water permeability is further connected to cell motility. AQPs of the aquaglyceroporin subfamily are necessary for lipid degradation in adipocytes and glycerol uptake into the liver, as well as for skin moistening. Modulation of AQP function is desirable in several pathophysiological situations, such as nephrogenic diabetes insipidus, Sjögren's syndrome, Menière's disease, heart failure, or tumors to name a few. Attempts to design or to find effective small molecule AQP inhibitors have yielded only a few hits. Challenges reside in the high copy number of AQP proteins in the cell membranes, and spatial restrictions in the protein structure. This review gives an overview on selected physiological and pathophysiological conditions in which modulation of AQP functions appears beneficial and discusses first achievements in the search of drug-like AQP inhibitors.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aquaporin; Drug development; Glycerol; Inhibition; Volume regulation; Water

Mesh:

Substances:

Year:  2015        PMID: 26277280     DOI: 10.1016/j.pharmthera.2015.08.002

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  22 in total

1.  Bioinformatics analysis and construction of phylogenetic tree of aquaporins from Echinococcus granulosus.

Authors:  Fen Wang; Bin Ye
Journal:  Parasitol Res       Date:  2016-05-11       Impact factor: 2.289

Review 2.  Revisiting the metabolic syndrome: the emerging role of aquaglyceroporins.

Authors:  Inês Vieira da Silva; Joana S Rodrigues; Irene Rebelo; Joana P G Miranda; Graça Soveral
Journal:  Cell Mol Life Sci       Date:  2018-02-20       Impact factor: 9.261

Review 3.  Aquaporin-Targeted Therapeutics: State-of-the-Field.

Authors:  Lukmanee Tradtrantip; Bjung-Ju Jin; Xiaoming Yao; Marc O Anderson; Alan S Verkman
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 4.  Aquaporins in lung health and disease: Emerging roles, regulation, and clinical implications.

Authors:  Ekta Yadav; Niket Yadav; Ariel Hus; Jagjit S Yadav
Journal:  Respir Med       Date:  2020-10-17       Impact factor: 3.415

5.  Experimental Evaluation of Proposed Small-Molecule Inhibitors of Water Channel Aquaporin-1.

Authors:  Cristina Esteva-Font; Byung-Ju Jin; Sujin Lee; Puay-Wah Phuan; Marc O Anderson; A S Verkman
Journal:  Mol Pharmacol       Date:  2016-03-18       Impact factor: 4.436

Review 6.  Lipids in the Bone Marrow: An Evolving Perspective.

Authors:  Elizabeth Rendina-Ruedy; Clifford J Rosen
Journal:  Cell Metab       Date:  2019-10-24       Impact factor: 27.287

Review 7.  Hepatocyte and Sertoli Cell Aquaporins, Recent Advances and Research Trends.

Authors:  Raquel L Bernardino; Raul A Marinelli; Anna Maggio; Patrizia Gena; Ilaria Cataldo; Marco G Alves; Maria Svelto; Pedro F Oliveira; Giuseppe Calamita
Journal:  Int J Mol Sci       Date:  2016-07-09       Impact factor: 5.923

Review 8.  Detecting Aquaporin Function and Regulation.

Authors:  Ana Madeira; Teresa F Moura; Graça Soveral
Journal:  Front Chem       Date:  2016-02-01       Impact factor: 5.221

Review 9.  Recent Update on the Molecular Mechanisms of Gonadal Steroids Action in Adipose Tissue.

Authors:  Agata Wawrzkiewicz-Jałowiecka; Anna Lalik; Graça Soveral
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

10.  Pentamidine Is Not a Permeant but a Nanomolar Inhibitor of the Trypanosoma brucei Aquaglyceroporin-2.

Authors:  Jie Song; Nicola Baker; Monja Rothert; Björn Henke; Laura Jeacock; David Horn; Eric Beitz
Journal:  PLoS Pathog       Date:  2016-02-01       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.